These results indicate that, while KRAS and NRAS tend to exhibit mutually exclusive mutation patterns, mutations in signaling molecules downstream of EGFR may co-exist with KRAS and NRAS alterations in colorectal tumors. Here, KRAS is linked to colorectal neoplasm.